BrightSpring Health Services’ first quarter results drew a strong positive market reaction, as management credited robust demand for home and community-based care and effective execution across its pharmacy and provider businesses. CEO Jon Rousseau highlighted that the quarter’s performance was powered by significant volume growth in specialty pharmacy, operational efficiency initiatives, and new therapy launches. Notably, Rousseau pointed to BrightSpring’s expanding specialty drug portfolio and investments in technology as key contributors, stating, “Specialty script growth was 32% in the first quarter, a reflection of innovative new therapies coming to market and our ability to serve as a strong partner to prescribing physicians and patients and their families.”
Is now the time to buy BTSG? Find out in our full research report (it’s free).
BrightSpring Health Services (BTSG) Q1 CY2025 Highlights:
- Revenue: $2.88 billion vs analyst estimates of $2.75 billion (11.7% year-on-year growth, 4.6% beat)
- Adjusted EPS: $0.19 vs analyst estimates of $0.09 (significant beat)
- Adjusted EBITDA: $131.1 million vs analyst estimates of $125.6 million (4.6% margin, 4.4% beat)
- The company lifted its revenue guidance for the full year to $12.25 billion at the midpoint from $11.85 billion, a 3.4% increase
- EBITDA guidance for the full year is $577.5 million at the midpoint, above analyst estimates of $563.1 million
- Operating Margin: 1.8%, up from -0.6% in the same quarter last year
- Market Capitalization: $3.97 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions BrightSpring Health Services’s Q1 Earnings Call
- Whit Mayo (Leerink Partners) pressed for details on what drove the surge in gross profit per script. CFO Jen Phipps cited favorable product mix, procurement efforts, and a focus on generics as primary contributors.
- Ann Hynes (Mizuho) asked whether the Inflation Reduction Act could lead to usage changes among patients or physicians. Phipps responded that management does not expect meaningful shifts in utilization or financial impact from IRA at this stage.
- Joanna Gajuk (Bank of America) questioned the sustainability of gross profit per script growth with upcoming generic launches. Phipps explained that mix and procurement will continue to drive performance, and the generic pipeline remains strong.
- David Larsen (BTIG) inquired about the impact of potential pharmaceutical tariffs on costs and reimbursement. CEO Jon Rousseau and Phipps indicated that current contracts and inventory levels should shield 2025 results, with reimbursement typically adjusting to cost changes.
- Brian Tanquilut (Jefferies) asked if the company’s involvement in acquisition activity signals more deal flow in provider services and its impact on leverage. Rousseau said any deals align with BrightSpring’s philosophy of disciplined, accretive tuck-ins and do not alter leverage targets.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will be watching (1) the pace and success of new specialty and generic drug launches in the pharmacy segment, (2) the realization of margin expansion from lean operational initiatives and technology upgrades, and (3) regulatory developments around pharmaceutical tariffs and the Inflation Reduction Act that could affect cost structures and reimbursement. Execution on M&A integration and contract wins in provider services will also be important signals of strategic progress.
BrightSpring Health Services currently trades at $23.08, up from $17.89 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).
The Best Stocks for High-Quality Investors
The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.
While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
